Trial Profile
A study to evaluate the efficacy of Blinatumomab along with Tyrosine Kinase Inhibitors in the treatment of patients with relapsed/refractory acute lymphoblastic leukemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Dec 2017
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 12 Dec 2017 Results assessing efficacy and toxicity of Blinatumomab presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 21 Jul 2017 New trial record